- Previous Close
0.0000 - Open
5.9500 - Bid 4.8600 x --
- Ask 5.8600 x 34100
- Day's Range
5.9500 - 5.9500 - 52 Week Range
4.3200 - 5.9500 - Volume
100 - Avg. Volume
24 - Market Cap (intraday)
148.753M - Beta (5Y Monthly) 0.88
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0200 - Earnings Date May 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date May 23, 2013
- 1y Target Est
--
Photocure ASA, together with its subsidiaries, engages in the research, development, production, distribution, marketing, and sale of pharmaceutical products in Nordic countries, Germany, France, Austria, the United Kingdom, the BeNeLux, Italy, other European Countries, Canada, and the United States. It operates through Commercial Franchise and Development Portfolio segments. The company offers Hexvix/Cysview for the detection and management of bladder cancer. It also develops Cevira for the treatment of human papilloma virus-induced cervical precancerous lesions. The company has a license agreement with Asieris MediTech Co to develop and commercialize Cevira, as well as strategic agreement with Richard Wolf GmbH to develop and commercialize a next-generation 4K LED high-definition (HD) reusable flexible blue light cystoscope based on Richard Wolf's System blue technology. It sells its products to pharmaceutical wholesalers, pharmacies, and hospitals through license partners. Photocure ASA was founded in 1993 and is headquartered in Oslo, Norway.
www.photocure.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: PHCUF
View More
Performance Overview: PHCUF
Trailing total returns as of 3/26/2025, which may include dividends or other distributions. Benchmark is OBX Total Return Index (OBX.OL) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PHCUF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PHCUF
View MoreValuation Measures
Market Cap
148.75M
Enterprise Value
120.83M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.35
Price/Book (mrq)
2.44
Enterprise Value/Revenue
2.42
Enterprise Value/EBITDA
17.16
Financial Highlights
Profitability and Income Statement
Profit Margin
-0.92%
Return on Assets (ttm)
1.76%
Return on Equity (ttm)
-0.98%
Revenue (ttm)
525.39M
Net Income Avi to Common (ttm)
-4.81M
Diluted EPS (ttm)
-0.0200
Balance Sheet and Cash Flow
Total Cash (mrq)
293.85M
Total Debt/Equity (mrq)
3.46%
Levered Free Cash Flow (ttm)
30.16M
Research Analysis: PHCUF
View MoreCompany Insights: PHCUF
PHCUF does not have Company Insights